Table 1.
Highly variable frequency in many tumors |
Total HLA class I antigen loss (9–52%) |
HLA class I downregulation (3–20%) |
Selective loss or downregulation of HLA class I allospecificities (15–50%) |
Association with disease progression |
Tissue and/or tumor subtype specificity |
Differentiation/cell cycle dependence |